Addressing the link between paraoxonase-1 gene variants and the incidence of early onset myocardial infarction

Mohamed F. Abdel Rahman, Ingy M. Hashad, Khaled Abou-Aisha, Sahar M. Abdel-Maksoud, Mohamed Z. Gad

Clinical Biochemistry Unit, Faculty of Pharmacy and Biotechnology, German University, Cairo, Egypt

Submitted: 27 February 2014
Accepted: 19 April 2014

Arch Med Sci 2015; 11, 3: 513–520
DOI: 10.5114/aoms.2015.52353
Copyright © 2015 Termedia & Banach

Abstract

Introduction: The enzyme paraoxonase-1 (PON1) represents an endogenous defense mechanism against vascular oxidative stress, thereby contributing to the prevention of atherosclerosis. Several polymorphisms have been reported in the PON1 gene, including Q192R. PON1 phenotype is commonly expressed as the paraoxonase/arylesterase ratio (PON/ARE). The major aim of this study was to investigate the association between PON1 Q192R polymorphism, PON1 phenotypes and the incidence of early-onset acute myocardial infarction (AMI) in Egyptians.

Material and methods: The study subjects consisted of 102 AMI patients and 72 age-matched healthy controls. Genotyping and enzyme activities were determined using PCR-RFLP and kinetic spectrophotometric assays, respectively.

Results: The genotype distribution for the PON1 gene was significantly different between AMI patients (QQ = 38.24%, QR = 49.02%, RR = 12.75%) and controls (QQ = 66.67%, QR = 25%, RR = 8.33%). Allele frequencies were also significantly different between patients (Q = 62.75%, R = 37.25%) and controls (Q = 79.17%, R = 20.83%). The genotypes QR and RR showed higher risk for AMI compared to the homozygous QQ (odds ratio (OR) = 3.231, \( p < 0.001 \)). The average PON/ARE ratio in MI patients (1.187 ±0.1) did not differ significantly from controls (1.118 ±0.26). However, it showed a significant difference among different genotypes in both AMI patients (QQ = 0.91 ±0.11, QR = 1.09 ±0.11 and RR = 2.65 ±0.4) (\( p = 0.0002 \)) and controls (QQ = 0.68 ±0.1, QR = 1.07 ±0.11 and RR = 4.89 ±2.84) (\( p < 0.0001 \)).

Conclusions: PON1 192R allele represents an independent risk factor for early-onset AMI in Egyptians, and PON1 Q192R polymorphism modulates the paraoxonase phenotype.

Key words: paraoxonase, arylesterase, PON polymorphism, acute myocardial infarction, Egyptians.

Introduction

Myocardial infarction (MI) is a complex multifactorial polygenic disorder that is thought to result from an interaction between a person’s genetic makeup and various environmental factors [1]. In general, there are several conventional risk factors for occurrence of MI including hypertension, diabetes mellitus, and hypercholesterolemia. Although each
HDL has long been known to show an inverse correlation with high-density lipoprotein (HDL). This most likely explains its ability to metabolize lipid peroxides and to protect against their accumulation on low-density lipoprotein (LDL) [9]. The serum concentration of HDL is synthesized in the liver and is closely associated with high-density lipoprotein (HDL). This most likely explains its ability to metabolize lipid peroxides and to protect against their accumulation on low-density lipoprotein (LDL) [9]. The serum concentration of HDL has long been known to show an inverse correlation with the development of atherosclerosis. Some studies have demonstrated decreased serum paraoxonase activity in survivors of myocardial infarction [10, 11].

The PON1 gene has 2 common polymorphisms in the coding region, which lead to a glutamine-to-arginine substitution at position 575A>G (PON1 Q192R) and a leucine to-methionine substitution at position 163T>A (PON1 L55M). Both independently influence PON1 activity and have been referred to as the molecular basis for this inter-individual variability [12]. Genetic polymorphisms that affect PON1 could be predisposing risk factors both in environmental toxicology and in cardiovascular diseases. The PON1 polymorphisms are important in determining the capacity of HDL to protect LDL against oxidative modification in vitro, which may explain the relationship between the PON1 alleles and coronary heart disease in case-control studies [13]. However, it was suggested that PON1 phenotype (enzyme activity) is a better predictor of vascular disease than PON1 genotype [14].

The PON1 192 activity polymorphism is substrate dependent. It was reported by some studies that the PON1 R192 isoform has higher activity for the hydrolysis of paraoxon [15], while both isoforms hydrolyze phenylacetate at approximately the same rate [16]. The PON1 phenotype is expressed as the paraoxonase/arylesterase ratio (PON/ARE) as the arylesterase activity is generally accepted to be a measure of PON1 serum enzyme level [17].

The aim of the current study was to investigate the association between the PON1 Q192R polymorphism and early onset acute myocardial infarction (AMI) and to correlate PON/ARE with AMI in the male Egyptian population.

**Material and methods**

**Study population**

One hundred and two random unrelated AMI patients, divided into 36 women (age range 34 to 55 years) and 66 men (age range 35 to 55 years) were recruited from the intensive care unit of the National Heart Institute, Imbaba, Giza. Seventy-two random unrelated healthy controls were recruited for the study from the volunteers attending the blood bank at 57357 Hospital in Cairo, Egypt. Out of the controls, 13 were women, aged between 26 and 42 years, and 59 were men, 25 to 55 years of age.

Patients were included if they had a diagnosis of an acute single or multi-vessel coronary artery disease (CAD) verified by clinical presentation, ECG changes, and/or elevation of cardiac markers. Written informed consent was obtained from each participant in the study that abided by the Helsinki declaration. Information on personal and family medical history and health-relevant behaviors, including exercise and diet, was obtained by a routine questionnaire filled in by blood donors at the time of venesection. Exclusion criteria for both patients and controls included any concomitant acute or chronic severe diseases such as renal failure, hepatic insufficiency, cardiovascular disease other than MI, and diabetes mellitus.

**Specimen collection**

Fasting blood samples (4 ml) were collected into 2 sets of tubes; the first set consisted of EDTA-coated vacuum tubes stored at 4°C for DNA extraction. The second set consisted of non-EDTA-coated vacuum tubes, which were centrifuged at 1000 rpm for 10 min, and the resulting serum was separated and stored at −20°C in 0.25 ml aliquots. The aliquots were used for determination of PON and ARE activities.

**Determination of the PON1 Q192R polymorphism**

Genomic DNA was prepared from blood leukocytes by the QIAamp DNA Mini Kit (QIAGEN). Determination of the PON1 Q192R polymorphism was carried out by PCR followed by restriction digestion (PCR-RFLP restriction fragment length polymorphism). The primers used were: forward: 5'-TGTTCATTATAGCTAGCAGA-3' and reverse: 5'-TTCACCCCCCTGAAATTA-3'. The resulting PCR...
product size was 496 bp. The nucleotide substitution corresponding to position 192 (Q/R) creates an AlwI (New England Biolabs) restriction site. Digestion resulted in 287- and 209-bp fragments for the R allele (Figure 1) [18].

**Assay of serum PON activity**

The PON activity was determined using paraoxon as a substrate and measured by increases in the absorbance at 412 nm due to the formation of 4-nitrophenol. The activity was measured at 25°C by adding 50 μl of serum to 1 ml of Tris-HCl buffer (100 mM at pH 8.0) containing 2 mM CaCl₂ and 5 mM paraoxon. The rate of generation of 4-nitrophenol was determined at 412 nm. Enzymatic activity was calculated by using the molar extinction coefficient 17 100 M⁻¹ cm⁻¹ [19]. One unit (U) of paraoxonase activity produced 1 μmol of p-nitrophenol per min [20].

**Assay of serum ARE activity**

ARE activity was measured using phenylacetate as a substrate. Serum was diluted 400-fold in 100 mM Tris-HCl buffer, pH = 8.0. The reaction mixture contained 2.0 mM phenylacetate and 2.0 mM CaCl₂ in 100 mM Tris-HCl buffer, pH = 8.0. Initial rates of hydrolysis were determined by following the increase of phenol concentration at 270 nm at 25°C [19]. One unit (U) of arylesterase activity is equal to 1 μmol of phenyl acetate per minute [21].

**Assay of lipid parameters**

Serum oxidized LDL (ox-LDL) was determined by quantitative enzyme-linked immunosorbent assay (ELISA) using a commercial kit provided by Immunodagnostik, Germany [22]. Serum triacylglycerols (TG) and total cholesterol (TC) were determined using an enzymatic colorimetric assay according to the methods of Wahlefeld and Richmond, respectively, using diagnostic kits provided by Stanbio Laboratory, USA [23, 24].

**Data processing and statistical analysis**

All statistical analysis was performed using the statistical programs SPSS and GraphPad Prism. Data are represented as mean ± SEM. To compare differences between groups, odds ratio, Student t-test and one-way analysis of variance (ANOVA) were used. A two-tailed p value ≤ 0.05 was considered statistically significant.

**Results**

**Genotyping of PON1 Q192R polymorphism**

The genotype distribution for the PON1 gene was significantly different between AMI patients (QQ = 38.24%, QR = 49.02% and RR = 12.75%) and controls (QQ = 66.67%, QR = 25%, RR = 8.33%) (Mann-Whitney test, p = 0.0006) (Figure 2). The corresponding allele frequencies were significant as well; patients were Q = 62.75% and R = 37.25% and controls Q = 79.17% and R = 20.83% (Mann-Whitney test, p = 0.0011) (Figure 3). The odd ratio between QQ genotype and QR + RR genotypes was 3.231 (p < 0.001), while the odd ratio between the Q allele and the R allele was 2.256 (p = 0.001).

**PON phenotyping**

No significant difference was observed (Student t-test; p = 0.7413) between the PON activities in AMI patients (82.71 ±7.15 U/ml) (mean ± SEM) and controls (86.44 ±8.88 U/ml). PON/ARE ratio in MI patients (1.187 ±0.1) also did not differ significantly (Student t-test; p = 0.7851) from controls (1.118 ±0.26).
Correlation of PON1 genotypes with PON/ARE ratio in control and AMI subjects

There was a significant difference in the PON activities among the different genotypes in both AMI patients (QQ = 60.88 ±6.36, QR = 69.66 ±6.56 and RR = 222.7 ±20.75 U/ml) (Kruskal-Wallis; p < 0.0001) and control subjects (QQ = 65.58 ±7.9, QR = 101.4 ±14.15 and RR = 206.6 ±53.65 U/ml) (Kruskal-Wallis; p = 0.0025) (Figure 4). No significant difference was observed in the ARE activities among the different genotypes in both AMI patients (QQ = 79.56 ±6.62, QR = 69.08 ±4.73 and RR = 95.2 ±11.38 U/ml) (Kruskal-Wallis; p = 0.1170) and control subjects (QQ = 106.9 ±6.86, QR = 101.5 ±10.54 and RR = 86.28 ±31.62 U/ml) (Kruskal-Wallis; p = 0.8092) (Figure 5). On the other hand, PON/ARE ratios showed a significant difference among different genotypes in both AMI patients (QQ = 0.91 ±0.11, QR = 1.09 ±0.11 and RR = 2.65 ±0.4) (Kruskal-Wallis; p = 0.0002) and control subjects (QQ = 0.68 ±0.1, QR = 1.07 ±0.11 and RR = 4.89 ±2.84) (Kruskal-Wallis; p < 0.0001) (Figure 6).

Results of lipid profile

A summary of lipid profile data in AMI and controls is shown in Table I. A highly significant dif-
ference was observed in the levels of ox-LDL and TG in AMI relative to those of controls. However, TC was not significantly affected, as most patients were on hypocholesterolemic therapy. The significant difference in ox-LDL and TG in AMI patients was not reflected in noticeable differences among the different PON genotypes (Table II).

**Discussion**

**Genotyping of PON1 Q192R polymorphism**

Many reports have provided evidence that PON1 has a protective role from cardiovascular disease due to its ability to inhibit LDL oxidation *in vitro*. The role of PON1 in vascular protection was supported by knockout and transgenic mouse studies. While knockout mice lacking serum PON1 have an increased susceptibility to atherosclerosis [25], human PON1 transgenic mice with 2- to 4-fold increased PON1 levels have reduced susceptibility [26]. The SREBP-2 (an important cholesterol transcriptional regulator) present in the region from bp –104 to –95 in the proximal PON1 promoter suggests an important PON1-lipoprotein relationship, as SREBP-2 was found to increase PON1 promoter activity in a dose-dependent manner, indicating an additional lipid-related mechanism of PON1 activation [27].

The two most common PON1 coding region polymorphisms are 192 Gln(Q)/Arg(R) and 55 Leu(L)/Met(M). Recently, several studies aimed to explore the relationship between PON1 polymorphisms and the risk of coronary artery disease.

This study investigated the clinical significance of PON1 Q192R polymorphism in CAD in an Egyptian population. The study results showed that subjects having genotypes QR + RR have a significantly higher risk for development of AMI than QQ subjects, suggesting that the PON1 R allele is less efficient at retarding the oxidation of LDL than is the Q allele. These results are supported by Mackness et al., who observed decreased hydrolysis of lipid peroxides by the R allele [28]. The R allele frequency among our studied AMI patients was also significantly different from control subjects.

These results are consistent with a meta-analysis carried out in 2001 which demonstrated an increase in the frequency of the PON1-192R allele in coronary heart disease (CHD) patients [13]. The results were also consistent with several studies carried out in Euro- and Afro-Brazilian [29], Indian [30, 31], Turkish [32, 33], and Polish populations [34] and also with another study performed on the Egyptian population [35]. All these studies showed that genotype distributions and allele frequencies of the PON1 Q192R polymorphism were significantly different between control subjects and AMI patients.

However, our study results were in contrast with others done on Japanese [36], British [13], German [37], Portuguese [38], American [39], Brazilian [40], Turkish [41–43] and Finnish [44] populations which showed that genotype distributions and allele frequencies of the PON1 Q192R polymorphism were not significantly different between control subjects and AMI patients. The inconsistent association of PON1 with CAD may be attributed to the variable factors among studies including ethnicity, environmental factors, sampling scheme and trial size.

**PON phenotyping**

The results showed that the PON activities among AMI patients were slightly lower than PON activities in control subjects; however, the difference was not significant. The difference in PON/ARE ratios was not significant as well. So far there have been only a few studies that have assessed PON1 activity in CAD. These studies showed that the PON activities [11, 45, 46] and ARE activities [11, 46] are significantly lower in AMI patients than control subjects. Our results are in harmony with these studies in ARE results; however, the insignificant difference in the PON activities in the current study might be explained by the relatively young age of our study subjects compared to others.

| Parameter          | AMI         | Controls     |
|--------------------|-------------|--------------|
| Total cholesterol  | 208.6 ±6.20 | 219.7 ±9.07  |
| Total triglycerides| 162.1 ±7.89*| 110.8 ±7.57  |
| Ox-LDL [ng/ml]     | 203.4 ±21.33* | 113.5 ±4.9   |

*Significant difference was observed; p < 0.0001.

| AMI     | QQ     | QR     | RR     | Value of p  |
|---------|--------|--------|--------|-------------|
| Total cholesterol [mg/dl] | 211.8 ±11.74 | 205.3 ±7.64 | 211.0 ±15.57 | 0.7968      |
| Total triglycerides [mg/dl] | 148.6 ±11.65 | 174.3 ±11.73 | 159.3 ±24.58 | 0.3420      |
| Ox-LDL [ng/ml] | 189.9 ±34.02 | 196.9 ±27.68 | 208.7 ±86.57 | 0.8515      |

**Table I.** Summary of lipid profile data in study groups

**Table II.** Summary for the total cholesterol, total triglycerides and oxidized LDL (ox-LDL) in different variants of PON1 Q192R polymorphism in AMI patients
Correlation of PON1 genotypes with PON/ARE ratio in control and AMI subjects

In the current study both patients and controls with RR genotype had the highest serum paraoxonase activities, followed by QR then QQ. The difference in PON activities was significant in the AMI patients as well as the control subjects; however, the arylesterase activities of paraoxonase enzyme did not change significantly among different PON1 Q192R variants either in the AMI patients or in the control subjects. This was reflected in the PON/ARE ratios, which varied significantly with the PON1 Q192R polymorphism in both study groups. These results indicated that PON1 Q192R polymorphism modulates the PON activity without affecting the ARE activity of the enzyme. The results are consistent with previous studies that investigated the relationship between the PON1 Q192R polymorphism and the phenotype of the enzyme [14–17]. Mackness et al. [48] suggested that the polymorphism does not appear to affect the synthesis and secretion or clearance, but might have an effect on the protein conformation or binding to HDL altering its substrate specificity.

Demonstration of 192RR as a risk factor for AMI seems contradictory to its high paraoxonase activity. Despite the familiarity of the use of paraoxon as a substrate to assay for PON activity, the direct relationship between the hydrolytic activity of PON1 against organophosphate substrates such as paraoxon and the protection against LDL oxidation is still not fully understood. While the organophosphate hydrolytic activity of PON1 is highly calcium dependent, it was found that the sulfhydryl group at amino acid position 283, not calcium, is essential to prevent the accumulation of lipid peroxides [49]. This suggests either that conformational changes in the active site of PON1 take place to shift the enzyme from hydrolytic to antioxidant activity, or that the enzyme possesses two active sites: the antioxidant site, dependent on Cys283, and the hydrolytic site, dependent on calcium. In either case, it cannot be assumed that the capacity to hydrolyze substrates such as paraoxon or phenylacetate necessarily reflects the presence or absence of significant PON1 antioxidant capacity [9].

In conclusion, although it was suggested that the PON phenotype is more important than genotype [14], our results suggest that carrying the PON1 192R allele represents an independent risk factor for early onset AMI in the Egyptian population. Among the limitations of this study is the narrow selection of MI patients with regard to number, sex and age. Further, wider studies are still required to unravel the exact physiological role of PON and the nature of its physiological substrate.

Acknowledgments

This study was supported by the Science and Technology Development Fund (STDF), grant no. 2951.

Conflict of interest

The authors declare no conflict of interest.

References

1. Marenberg ME, Risch N, Berkman LE, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-6.
2. Nora JJ, Lortscher RH, Spangler RD, Nora AH, Kimberling WJ. Genetic-epidemiologic study of early-onset ischemic heart disease. Circulation 1980; 61: 503-8.
3. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347: 1917-23.
4. Mazur A. An enzyme in animal tissues capable of hydrolyzing the phosphorus fluorine bond of alkyl fluorophosphates. J Biol Chem 1946; 164: 271-89.
5. Gupta N, Gill K, Singh S. Paraoxonases: structure, gene polymorphism and role in coronary artery disease. Indian J Med Res 2009; 130: 361-8.
6. Mackness B, Turkie W, Mackness M. Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease. Arch Med Sci 2013; 9: 8-13.
7. Mochizuki H, Scherer SW, Xi T, et al. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998; 213: 149-57.
8. Beltowski J, Wojcicka G, Marciniak A. Species- and substrate-specific stimulation of human plasma paraoxonase 1 (PON1) activity by high chloride concentration. Acta Biochim Pol 2002; 49: 927-36.
9. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-80.
10. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Determination of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32: 671-3.
11. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-5.
12. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B alleles. Am J Hum Genet 1993; 52: 598-608.
13. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-7.
Addressing the link between paraoxonase-1 gene variants and the incidence of early onset myocardial infarction

14. Jarvik GP, Rozek LS, Brophy VH, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than PON1(192 Q) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-7.

15. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase arylesterase polymorphism. Nat Genet 1993; 3: 73-6.

16. La Du BN, Piko JL, Eckerson HW, Vincent-Viry M, Sies G. An improved method for phenotyping individuals for the human serum paraoxonase arylesterase activity. Ann Biol Clin 1986; 44: 369-72.

17. Can Demirgogen B,Turkanoğlu A, Bek S, et al. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem 2008; 41: 1-9.

18. Hashemi M, Moazeni-Roodi AK, Fazaeli A, et al. Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Biol 2010; 9: 333-9.

19. Altindag O, Gur A, Calgan N, Soran N, Celik H, Selik S. Paraoxonase and arylesterase activities in fibromyalgia. Redox Rep 2007; 12: 134-8.

20. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-27.

21. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19: 100-6.

22. Craig WY. Autoantibodies against oxidized low density lipoprotein: a review of clinical findings and assay methodology. J Clin Lab Anal 1995; 9: 70-4.

23. Wahlefeld AW. Triglycerides: determination after enzymatic hydrolysis. In: Method of enzymatic analysis, in Verlag Chemie. Bergmeyer HV (ed.). Academic Press, New York 1974, 1831-5.

24. Richmond W. Preparation and properties of a cholesteryl oxidade from Nocardia sp. and its application to the enzymatic assay of total cholesteryl in serum. Clin Chem 1973; 19: 1350-6.

25. Shih DM, Ou L, Xia YR, et al. Niacin lowering serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-7.

26. Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 848-90.

27. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003; 23: 2083-9.

28. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998; 423: 57-60.

29. Allebrandt KV, Souza RL, Chauard-Freire-Maia EA. Variability of the paraoxonase gene (PON1) in Euro- and Afro-Brazilians. Toxicol Appl Pharmacol 2002; 180: 151-6.

30. Agrawal S, Tripathi G, Prajnya R, et al. Paraoxonase-1 gene polymorphisms contribute to coronary artery disease risk among north Indians. Indian J Med Sci 2009; 63: 335-44.

31. Lakshmy R, Ahmad D, Abraham RA, et al. Paraoxonase gene Q192R and L55M polymorphisms in Indians with acute myocardial infarction and association with oxidized low density lipoprotein. Indian J Med Res 2010; 131: 522-9.

32. Oezkok E, Aydin M, Babalik E, Ozbek Z, Ince N, Kara I. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. Med Sci Monit 2008; 14: CR536-42.

33. Hazar A, Dilmez F, Goz M, Kocarslan A, Aydin MS, Demirkol AH. The paraoxonase 1 (PON1) gene polymorphisms in coronary artery disease in the southeastern Turkish population. Turk J Med Sci 2011; 41: 895-902.

34. Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J. The role of polymorphisms within paraoxonases (192 Gin/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology 2010; 61: 157-65.

35. Mohamed RH, Karam RA, Abd El-Aziz TA. The relationship between paraoxonase-1 192 polymorphism and activity with coronary artery disease. Clin Biochem 2010; 43: 553-8.

36. Hong SH, Song J, Min WK, Kim JQ. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem 2001; 34: 475-81.

37. Cascarbi J, Laule M, Mrozkiewicz PM, et al. Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics 1999; 9: 755-61.

38. Mendonca ML, Dos Reis RP, Freitas AL, et al. Gene-gene interaction affects coronary artery disease risk. Rev Port Cardiol 2009; 28: 397-415.

39. Thyagarajan B, Jacobs DR Jr, Carr JJ, et al. Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem 2008; 54: 738-46.

40. Oliveira SA, Mansur AP, Ribeiro CC, Ramires JA, Anichino-Bazzichi JM. PON1 M55/L55 mutation protects high-risk patients against coronary artery disease. Int J Cardiol 2009; 136: 73-7.

41. Aynacioglu AS, Kepekci Y. The human paraoxonase Gln-Arg92 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int J Cardiol 2000; 74: 33-7.

42. Taskiran P, Cam SF, Sekuri C, et al. [The relationship between paraoxonase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease]. Turk Kardiyol Dern Ars 2009; 37: 473-8.

43. Kaman D, Ilhan N, Metin K, Akbulut M, Ustundag B. The molecular basis of the human paraoxonase arylesterase activity polymorphism. Nat Genet 1993; 3: 73-6.

44. Malin R, Knutti JL, Janatuinen T, et al. Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med (Berl) 2001; 79: 449-58.

45. Mackness B, Durrington PN, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-9.

46. Doneva-Basheva K, Anastasov A, Postadzhyan A, Karamyan A. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. Int J Cardiol 2000; 74: 33-7.

47. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Brazilians. Toxicol Appl Pharmacol 2002; 180: 151-6.
48. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997; 122: 265-8.

49. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998; 18: 1617-24.